Title: Re: Biopatch vs Algidex
I agree with you on this one Lynn.  I looked around for any studies on silver being used on CVC's and came up with zilch, and there is nothing comparing the two (biopatch and silver product) together yet.  The savings between biopatch and the silver product is nothing to sneeze at, but one line infection in one person can cost anywhere from 30,000 to 50,000 dollars.  Kind of blows the savings on the product out of the water doesn't it?  It would be good to see some studies done though.
 
Heather Nichols RN BSN CRNI
Infusion Services
University of Louisville Trauma Institute
530 S. Jackson St.
Lou. Ky. 40202
(502)562-3530

>>> "Lynn Hadaway" <[EMAIL PROTECTED]> 5/19/2006 9:39 AM >>>
Is this the tradename for a silver impregnated dressing? If so, silver has a long history of use as an anti-infective agent, but there are no clinical studies available yet on the outcomes of using it on CVCs. Also no comparison studies to Biopatch that I have found. These studies require time and I don't know if they have been in use long enough to have a study published yet. So the only thing you may have to rely upon is the manufacturers bench testing. While this may be a good start, we do need clinical studies. Lynn


At 2:48 PM -0700 5/18/06, Kristin Robertson wrote:
Hi all.  We just received samples and info on the new Algidex patch.  We haven't trialed them yet. The savings to switch from Biopatch to Algidex is @ $18,000.00 annually. Any thoughts or personal experiences with Algidex? Any good studies comparing the two out there yet?
 
Thanks, Kristin


Kristin C. Robertson R.N.
Vascular Access Specialist


-- 
Lynn Hadaway, M.Ed., RNC, CRNI
Lynn Hadaway Associates, Inc.
126 Main Street, PO Box 10
Milner, GA 30257
http://www.hadawayassociates.com
office 770-358-7861


-----------------------------------------------------
Confidentiality Disclaimer

This message, including any attachments, is confidential, intended only for the named recipient(s) and may contain information that is privileged or exempt from disclosure under applicable law, including PHI (Protected Health Information) covered under the Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If you are not the intended recipient(s), you are notified that the dissemination, distribution, or copying of this message is strictly prohibited.  If you receive this message in error, or are not the named recipient(s), please notify the sender or contact the University of Louisville Health Care I.S. helpdesk at 502.562.3637 to report an inadvertently received message.

-----------------------------------------------------

BEGIN:VCARD
VERSION:2.1
X-GWTYPE:USER
FN:Nichols, Heather
TEL;WORK:562-3530
ORG:;IV specialist
EMAIL;WORK;PREF;NGW:[EMAIL PROTECTED]
N:Nichols;Heather
TITLE:RN
END:VCARD

Reply via email to